HUITAI Biomedicine Co., Ltd., located in the dynamic city of Chengdu in southwestern China, is a clinical-stage biotechnology company. Our vision is to lead the way in developing innovative treatments for fibrotic diseases, leveraging the safety and efficacy of small peptide therapeutics.

Committed to creating breakthrough treatments for the most severe fibrotic diseases that impact the lungs, liver, kidneys, and other critical organs, we design each of our products with a single-minded focus: significantly improving the benefit-risk ratio for patients, a key consideration in anti-fibrotic therapy.

Our drive is deeply personal; our company is proudly funded by its founders and executives, who have been personally touched by pulmonary fibrosis, losing loved ones to this devastating condition. Their passion for finding a cure powers our unwavering quest for medical breakthroughs that can significantly improve the quality of life for those affected.